Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million

Dow Jones05-15

By Dean Seal

Takeda Pharmaceutical will pay $13.7 million to resolve the Justice Department's allegations that it paid kickbacks to healthcare providers for prescribing its antidepressant Trintellix.

The government said Thursday that Takeda's U.S. unit agreed to settle claims that, via the alleged kickback scheme, it knowingly caused the submission of false claims to Medicare and other federal health care programs.

The Justice Department alleged that from 2014 to October 2020, Takeda gave paid speaking opportunities and meals at high-end restaurants to healthcare professionals, with the intention of getting them to prescribe its antidepressant medication Trintellix.

Takeda denies the government's allegations, and its settlement isn't an admission of facts or liability, according to court documents. A representative for the Japanese drugmaker didn't immediately respond to a request for comment.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

By Dean Seal

Takeda Pharmaceutical will pay $13.7 million to resolve the Justice Department's allegations that it paid kickbacks to healthcare providers for prescribing its antidepressant Trintellix.

The government said Thursday that Takeda's U.S. unit agreed to settle claims that, via the alleged kickback scheme, it knowingly caused the submission of false claims to Medicare and other federal health care programs.

The Justice Department alleged that from 2014 to October 2020, Takeda gave paid speaking opportunities and meals at high-end restaurants to healthcare professionals, with the intention of getting them to prescribe its antidepressant medication Trintellix.

The Japanese drugmaker denies the government's allegations, and its settlement isn't an admission of facts or liability, according to court documents.

"Takeda has not admitted wrongdoing of any kind," a spokesperson for the company said. "We are pleased to conclude this matter."

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

May 14, 2026 16:55 ET (20:55 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635772819?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 03:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635772819","market":"sg","top_or_hot":-1,"title":"Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Takeda Pharmaceutical will pay $13.7 million to resolve the Justice Department's allegations that it paid kickbacks to healthcare providers for prescribing its antidepressant Trintellix. \n</p>\n<p>\n  The government said Thursday that Takeda's U.S. unit agreed to settle claims that, via the alleged kickback scheme, it knowingly caused the submission of false claims to Medicare and other federal health care programs. \n</p>\n<p>\n  The Justice Department alleged that from 2014 to October 2020, Takeda gave paid speaking opportunities and meals at high-end restaurants to healthcare professionals, with the intention of getting them to prescribe its antidepressant medication Trintellix. \n</p>\n<p>\n  Takeda denies the government's allegations, and its settlement isn't an admission of facts or liability, according to court documents. A representative for the Japanese drugmaker didn't immediately respond to a request for comment. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Takeda Pharmaceutical will pay $13.7 million to resolve the Justice Department's allegations that it paid kickbacks to healthcare providers for prescribing its antidepressant Trintellix. \n</p>\n<p>\n  The government said Thursday that Takeda's U.S. unit agreed to settle claims that, via the alleged kickback scheme, it knowingly caused the submission of false claims to Medicare and other federal health care programs. \n</p>\n<p>\n  The Justice Department alleged that from 2014 to October 2020, Takeda gave paid speaking opportunities and meals at high-end restaurants to healthcare professionals, with the intention of getting them to prescribe its antidepressant medication Trintellix. \n</p>\n<p>\n  The Japanese drugmaker denies the government's allegations, and its settlement isn't an admission of facts or liability, according to court documents. \n</p>\n<p>\n  \"Takeda has not admitted wrongdoing of any kind,\" a spokesperson for the company said. \"We are pleased to conclude this matter.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 16:55 ET (20:55 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-15 03:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Takeda Pharmaceutical will pay $13.7 million to resolve the Justice Department's allegations that it paid kickbacks to healthcare providers for prescribing its antidepressant Trintellix. \n</p>\n<p>\n  The government said Thursday that Takeda's U.S. unit agreed to settle claims that, via the alleged kickback scheme, it knowingly caused the submission of false claims to Medicare and other federal health care programs. \n</p>\n<p>\n  The Justice Department alleged that from 2014 to October 2020, Takeda gave paid speaking opportunities and meals at high-end restaurants to healthcare professionals, with the intention of getting them to prescribe its antidepressant medication Trintellix. \n</p>\n<p>\n  Takeda denies the government's allegations, and its settlement isn't an admission of facts or liability, according to court documents. A representative for the Japanese drugmaker didn't immediately respond to a request for comment. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 15:54 ET (19:54 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635772819","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635772819","pubTimestamp":1778788440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Takeda Pharmaceutical will pay $13.7 million to resolve the Justice Department's allegations that it paid kickbacks to healthcare providers for prescribing its antidepressant Trintellix.The government said Thursday that Takeda's U.S. unit agreed to settle claims that, via the alleged kickback scheme, it knowingly caused the submission of false claims to Medicare and other federal health care programs.The Justice Department alleged that from 2014 to October 2020, Takeda gave paid speaking opportunities and meals at high-end restaurants to healthcare professionals, with the intention of getting them to prescribe its antidepressant medication Trintellix.Takeda denies the government's allegations, and its settlement isn't an admission of facts or liability, according to court documents. A representative for the Japanese drugmaker didn't immediately respond to a request for comment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TAK":"武田制药"},"translate_title":"武田制药以1370万美元和解司法部回扣案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Takeda Pharmaceutical will pay $13.7 million to resolve the Justice Department's allegations that it paid kickbacks to healthcare providers for prescribing its antidepressant Trintellix. \n\n\n  The government said Thursday that Takeda's U.S. unit agreed to settle claims that, via the alleged kickback scheme, it knowingly caused the submission of false claims to Medicare and other federal health care programs. \n\n\n  The Justice Department alleged that from 2014 to October 2020, Takeda gave paid speaking opportunities and meals at high-end restaurants to healthcare professionals, with the intention of getting them to prescribe its antidepressant medication Trintellix. \n\n\n  Takeda denies the government's allegations, and its settlement isn't an admission of facts or liability, according to court documents. A representative for the Japanese drugmaker didn't immediately respond to a request for comment. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n\n  By Dean Seal \n\n\n \n\n\n  Takeda Pharmaceutical will pay $13.7 million to resolve the Justice Department's allegations that it paid kickbacks to healthcare providers for prescribing its antidepressant Trintellix. \n\n\n  The government said Thursday that Takeda's U.S. unit agreed to settle claims that, via the alleged kickback scheme, it knowingly caused the submission of false claims to Medicare and other federal health care programs. \n\n\n  The Justice Department alleged that from 2014 to October 2020, Takeda gave paid speaking opportunities and meals at high-end restaurants to healthcare professionals, with the intention of getting them to prescribe its antidepressant medication Trintellix. \n\n\n  The Japanese drugmaker denies the government's allegations, and its settlement isn't an admission of facts or liability, according to court documents. \n\n\n  \"Takeda has not admitted wrongdoing of any kind,\" a spokesperson for the company said. \"We are pleased to conclude this matter.\" \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 16:55 ET (20:55 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635772819","isCrawlerRequest":true}